Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial

Open access
Jensen, Donald M., Marcellin, Patrick, Freilich, Bradley, Andreone, Pietro, Di Bisceglie, Adrian, Brandão-Mello, Carlos E., Reddy, K. Rajender, Craxi, Antonio, Martin, Antonio Olveira, Teuber, Gerlinde, Messinger, Diethelm, Thommes, James A., Tietz, Andreas · 2009 · Annals of Internal Medicine

Abstract

BACKGROUND: Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE: To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN: Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING: 106 international centers. PATIENTS: 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribavirin. INTERVENTION: Peginterferon-alpha2a, 360 microg/wk, for 12 weeks, then 180 microg/wk to complete 72 weeks (group A) or 48 weeks (group B), or peginterferon-alpha2a, 180 microg/wk for 72 weeks (group C) or 48 weeks (group D). All patients received ribavirin, 1000 or 1200 mg/d. MEASUREMENTS: Sustained virologic response (SVR), defined as undetectable (<50 IU/mL) HCV RNA levels 24 weeks after the end of treatment. RESULTS: The SVR rates in groups A (n = 317), B (n = 156), C (n = 156), and D (n = 313) were 16%, 7%, 14%, and 9%, respectively (relative risk [RR] for group A vs. group D [the primary comparison], 1.80 [95% CI, 1.17 to 2.77]; P = 0.006). Extended treatment duration increased SVR rates (16% for 72 weeks [groups A and C] vs. 8% for 48 weeks [groups B and D]; RR, 2.00 [CI, 1.32 to 3.02]; P < 0.001). Complete viral suppression (HCV RNA level <50 IU/mL)at week 12 was achieved in 21% of patients in groups A and B and 13% of those in groups C and D. Rates of SVR were 49% (77 of 157 patients) and 4% (32 of 719 patients) among those with and without complete viral suppression at week 12, respectively. LIMITATION: Nonresponders to peginterferon-alpha2a plus ribavirin were not evaluated. CONCLUSION: Re-treating nonresponders to therapy with peginterferon-alpha2b plus ribavirin for 72 weeks significantly increases SVR rates compared with re-treating them for 48 weeks. The overall SVR rate was low, but patients who are most likely to respond to re-treatment can be identified at week 12. PRIMARY FUNDING SOURCE: Roche.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-150-8-200904210-00007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Metadata

Authors
Jensen, D. M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandão-Mello, C. E., Reddy, K. R., Craxi, A., Martin, A. O., Teuber, G., Messinger, D., Thommes, J. A., & Tietz, A.
Venue
Annals of Internal Medicine
Published
2009-04-21
Volume
150
Issue
8
Pages
528-540
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2134194979
Cited by
175
References
1
FWCI
24.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-150-8-200904210-00007
The paper
Jensen, D. M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandão-Mello, C. E., Reddy, K. R., Craxi, A., Martin, A. O., Teuber, G., Messinger, D., Thommes, J. A., & Tietz, A. (2009). Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-8-200904210-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.